JP2025511145A5 - - Google Patents

Info

Publication number
JP2025511145A5
JP2025511145A5 JP2024557950A JP2024557950A JP2025511145A5 JP 2025511145 A5 JP2025511145 A5 JP 2025511145A5 JP 2024557950 A JP2024557950 A JP 2024557950A JP 2024557950 A JP2024557950 A JP 2024557950A JP 2025511145 A5 JP2025511145 A5 JP 2025511145A5
Authority
JP
Japan
Prior art keywords
carrier
solid dispersion
pharmaceutical formulation
pharmaceutical preparation
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024557950A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025511145A (ja
Filing date
Publication date
Priority claimed from PCT/CN2022/084214 external-priority patent/WO2023184282A1/en
Application filed filed Critical
Publication of JP2025511145A publication Critical patent/JP2025511145A/ja
Publication of JP2025511145A5 publication Critical patent/JP2025511145A5/ja
Pending legal-status Critical Current

Links

JP2024557950A 2022-03-30 2023-03-23 Ｘ８４２製剤 Pending JP2025511145A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2022/084214 WO2023184282A1 (en) 2022-03-30 2022-03-30 X842 formulation
CNPCT/CN2022/084214 2022-03-30
PCT/CN2023/083375 WO2023185624A1 (en) 2022-03-30 2023-03-23 X842 formulation

Publications (2)

Publication Number Publication Date
JP2025511145A JP2025511145A (ja) 2025-04-15
JP2025511145A5 true JP2025511145A5 (enExample) 2026-04-08

Family

ID=81386826

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024557950A Pending JP2025511145A (ja) 2022-03-30 2023-03-23 Ｘ８４２製剤

Country Status (8)

Country Link
US (1) US20260166014A1 (enExample)
EP (1) EP4499046A1 (enExample)
JP (1) JP2025511145A (enExample)
KR (1) KR20240165457A (enExample)
CN (2) CN119139298A (enExample)
AU (1) AU2023247528A1 (enExample)
MX (1) MX2024011716A (enExample)
WO (2) WO2023184282A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024230943A1 (en) * 2023-05-08 2024-11-14 Cinclus Pharma Holding AB (publ) Linaprazan glurate for treating gastroesophageal reflux disease (gerd)
WO2026032974A1 (en) 2024-08-05 2026-02-12 Cinclus Pharma Holding AB (publ) Formulation of linaprazan glurate

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1368006B1 (en) * 2001-02-13 2006-05-03 AstraZeneca AB Novel modified released formulation
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
CN101513403A (zh) * 2008-02-21 2009-08-26 上海慧德医药科技有限公司 含有苯并咪唑类化合物的药物制剂
FI20086158A0 (fi) 2008-12-03 2008-12-03 Mikael Dahlstroem Imidatsopyridiinijohdannaiset
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
CN106279151A (zh) * 2015-06-26 2017-01-04 江苏太瑞生诺生物医药科技有限公司 5-(2-(8-((2,6-二甲基苄基)氨基)-2,3-二甲基咪唑并[1,2-a]吡啶-6-甲酰胺基)乙氧基)-5-氧代戊酸的固体形式及其制备方法
US20210330599A1 (en) * 2016-08-01 2021-10-28 University Of Rochester Nanoparticles for Controlled Release of Anti-Biofilm Agents and Methods of Use
WO2020101860A1 (en) 2018-11-16 2020-05-22 Cnh Industrial America Llc System and method for aligning arms of an agricultural header
EP4054537B1 (en) * 2019-11-04 2023-06-07 Cinclus Pharma Holding AB (publ) Oral formulation of x842
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
US20220002297A1 (en) 2020-07-02 2022-01-06 Cinclus Pharma Ag Polymorphs of x842

Similar Documents

Publication Publication Date Title
ES2977953T3 (es) Comprimido
JP2005526043A5 (enExample)
JP2013199488A5 (enExample)
SK285300B6 (sk) Farmaceutická formulácia obsahujúca množinu liekových podjednotiek a spôsob jej výroby
JP2006502156A (ja) 風味を遮断された投与形態およびそれらの製剤の方法
CA2686094A1 (en) Manufacturing method of a semiconductor element
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
FR2940619A1 (fr) Composition comprenant un actif de solubilite aqueuse faible ou moyenne
CN103717223A (zh) 含甘磷酸胆碱或者其药学上可接受的盐的缓释药物组合物及其制造方法
RU2015107517A (ru) Фармацевтические композиции мемантина
US20250295596A1 (en) Multiparticulate oral dosage form providing prolonged release of tapentadol
US8563035B2 (en) Oral tablet compositions of dexlansoprazole
PT1711169E (pt) Minicomprimidos revestidos de libertação prolongada de cloridrato de venlafaxina.
ES2524261T3 (es) Formulación farmacéutica sólida
CH650922A5 (fr) Forme galenique d'administration du metoclopramide, son procede de preparation et medicament comprenant cette forme.
CA2906378C (en) Controlled release pharmaceutical dosage forms
WO2013054352A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
CN111902161A (zh) 含达比加群酯的药物组合物及其制备方法
CA2685214C (en) Improved controlled release oral dosage form
TR201918013A2 (tr) Propi̇veri̇n veya propi̇veri̇ni̇n farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren pellet kompozi̇syonu
EP2504370A1 (fr) Polymere de type acrylique ou methacrylique comprenant des greffons alpha-tocopherol
TR201801650T1 (tr) Kontrollü salim propi̇veri̇n formülasyonlari
EP2808019B1 (en) Improved nitazoxanide composition and preparation method thereof
NO875121L (no) Medikamenteringsform.
EP2221049A2 (en) Solid pharmaceutical composition of ded anosine